Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
06 12 2021
Historique:
received: 18 06 2021
revised: 21 08 2021
accepted: 28 09 2021
entrez: 14 10 2021
pubmed: 15 10 2021
medline: 26 10 2021
Statut: ppublish

Résumé

Adaptive immunity is a fundamental component in controlling COVID-19. In this process, follicular helper T (Tfh) cells are a subset of CD4+ T cells that mediate the production of protective antibodies; however, the SARS-CoV-2 epitopes activating Tfh cells are not well characterized. Here, we identified and crystallized TCRs of public circulating Tfh (cTfh) clonotypes that are expanded in patients who have recovered from mild symptoms. These public clonotypes recognized the SARS-CoV-2 spike (S) epitopes conserved across emerging variants. The epitope of the most prevalent cTfh clonotype, S864-882, was presented by multiple HLAs and activated T cells in most healthy donors, suggesting that this S region is a universal T cell epitope useful for booster antigen. SARS-CoV-2-specific public cTfh clonotypes also cross-reacted with specific commensal bacteria. In this study, we identified conserved SARS-CoV-2 S epitopes that activate public cTfh clonotypes associated with mild symptoms.

Identifiants

pubmed: 34647971
pii: 212701
doi: 10.1084/jem.20211327
pmc: PMC8641254
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Epitopes, T-Lymphocyte 0
HLA Antigens 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : 20fk0108265
Organisme : Japan Society for the Promotion of Science
ID : JP18H05279
Organisme : Kansai Economic Federation
Organisme : Mitsubishi Foundation
Organisme : AnGes
Organisme : Daicel
Organisme : FunPep

Informations de copyright

© 2021 Lu et al.

Déclaration de conflit d'intérêts

Disclosures: N. Sax reported personal fees from KOTAI Biotechnologies, Inc. outside the submitted work; in addition, N. Sax had a patent to "follicular helper T cells specific for SARS-CoV-2 virus" pending and a patent to "novel medical technology using follicular T cells" pending. H. Nakagami reported that the Department of Health Development and Medicine is an endowed department supported by Anges, Daicel, and Funpep. K. Yamashita reported personal fees from KOTAI Biotechnologies, Inc. outside the submitted work; in addition, K. Yamashita had a patent to "follicular helper T cells specific for SARS-CoV-2 virus" pending and a patent to "novel medical technology using follicular T cells" pending. No other disclosures were reported.

Références

Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
J Proteome Res. 2020 Jun 5;19(6):2304-2315
pubmed: 32308001
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Protein Eng. 2003 Sep;16(9):707-11
pubmed: 14560057
Nat Struct Mol Biol. 2021 Jun;28(6):478-486
pubmed: 33981021
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
Int Immunol. 2013 Apr;25(4):235-46
pubmed: 23334921
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
Trends Immunol. 2014 Sep;35(9):436-42
pubmed: 24998903
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5
pubmed: 20057045
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Methods Mol Biol. 2015;1282:99-108
pubmed: 25720475
J Exp Med. 2017 Jul 3;214(7):2139-2152
pubmed: 28637884
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2184-95
pubmed: 15572771
J Exp Med. 2019 Aug 5;216(8):1857-1873
pubmed: 31175140
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
J Clin Invest. 2016 Jun 1;126(6):2191-204
pubmed: 27183389
Science. 2017 Oct 20;358(6361):359-365
pubmed: 29051379
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Nat Microbiol. 2021 Jan;6(1):51-58
pubmed: 33199863
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Biochem Biophys Res Commun. 2021 Jan 1;534:680-686
pubmed: 33208230
Nat Genet. 2017 May;49(5):659-665
pubmed: 28369038
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Immunol Rev. 2013 Mar;252(1):139-45
pubmed: 23405901
J Immunol. 1992 Jan 1;148(1):249-58
pubmed: 1727870
J Clin Invest. 2020 Dec 1;130(12):6588-6599
pubmed: 32841212
J Virol. 2015 Mar;89(5):2684-97
pubmed: 25520514
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
mBio. 2021 Mar 2;12(2):
pubmed: 33653892
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
J Clin Invest. 2021 May 17;131(10):
pubmed: 33830946
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Science. 2015 Aug 28;349(6251):993-7
pubmed: 26272906
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Xiuyuan Lu (X)

Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Yuki Hosono (Y)

Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.

Masamichi Nagae (M)

Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Shigenari Ishizuka (S)

Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Eri Ishikawa (E)

Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Daisuke Motooka (D)

Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Yuki Ozaki (Y)

Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Nicolas Sax (N)

KOTAI Biotechnologies, Inc., Suita, Japan.

Yuichi Maeda (Y)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.

Yasuhiro Kato (Y)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Takayoshi Morita (T)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Ryo Shinnakasu (R)

Laboratory of Lymphocyte Differentiation, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Takeshi Inoue (T)

Laboratory of Lymphocyte Differentiation, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Taishi Onodera (T)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.

Takayuki Matsumura (T)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.

Masaharu Shinkai (M)

Tokyo Shinagawa Hospital, Tokyo, Japan.

Takashi Sato (T)

Tokyo Shinagawa Hospital, Tokyo, Japan.

Shota Nakamura (S)

Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Shunsuke Mori (S)

Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Laboratory of Immunochemistry, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Teru Kanda (T)

Division of Microbiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Emi E Nakayama (EE)

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Tatsuo Shioda (T)

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Center for Infectious Disease Education and Research, Osaka University, Suita, Japan.

Tomohiro Kurosaki (T)

Laboratory of Lymphocyte Differentiation, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Center for Infectious Disease Education and Research, Osaka University, Suita, Japan.
Laboratory of Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Kiyoshi Takeda (K)

Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
Center for Infectious Disease Education and Research, Osaka University, Suita, Japan.
Department of Mucosal Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.

Atsushi Kumanogoh (A)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Center for Infectious Disease Education and Research, Osaka University, Suita, Japan.

Hisashi Arase (H)

Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Laboratory of Immunochemistry, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Center for Infectious Disease Education and Research, Osaka University, Suita, Japan.

Hironori Nakagami (H)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Kazuo Yamashita (K)

KOTAI Biotechnologies, Inc., Suita, Japan.

Yoshimasa Takahashi (Y)

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.

Sho Yamasaki (S)

Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Center for Infectious Disease Education and Research, Osaka University, Suita, Japan.
Division of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba, Japan.
Division of Molecular Design, Research Center for Systems Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH